Early Therapeutic Antibody Development: Addressing the Challenges to Expedite a CMC Program.

Published on April 4, 2022

Learn how de-risk early-stage CMC and delivery of clinical trials material by addressing the challenges faced when therapeutic antibodies show less-than-ideal properties, from early development through to downstream manufacturing to pre-clinical and clinical studies.

The post Early Therapeutic Antibody Development: Addressing the Challenges to Expedite a CMC Program. appeared first on abzena.

Continue reading on website
Other news

Efficient Biological Drug Development Workflows: Lead Candidate to Drug Substance

April 4, 2022
Discover how to support a faster critical development path and reduce timelines to manufacture of drug substance and product for clinical trials with strategies for maximizing the overlap of activities during process development and manufacture, keeping DC selection options open for longer to generate better data with the aim of minimising risk.The discussion explores how the use of small-scale, a

Addressing Immunogenicity Challenges to Select the Best Drug Development Candidate.

April 4, 2022
De-risk and accelerate your programs by understanding some of the approaches to therapeutic protein immunogenicity risk assessment and how this helps you make better-informed candidate selection.The post Addressing Immunogenicity Challenges to Select the Best Drug Development Candidate. appeared first on abzena.